Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q16653
UPID:
MOG_HUMAN
Alternative names:
-
Alternative UPACC:
Q16653; A6NDR4; A6NNJ9; A8MY31; B0UZR9; E9PGF0; F8W9D5; O00713; O00714; O00715; Q13054; Q13055; Q14855; Q29ZN8; Q56UY0; Q5JNX7; Q5JNY1; Q5JNY2; Q5JNY4; Q5SSB5; Q5SSB6; Q5STL9; Q5STM0; Q5STM1; Q5STM2; Q5STM5; Q5SUK5; Q5SUK7; Q5SUK8; Q5SUK9; Q5SUL0; Q5SUL1; Q8IYG5; Q92891; Q92892; Q92893; Q92894; Q92895; Q93053; Q96KU9; Q96KV0; Q96KV1; Q99605
Background:
Myelin-oligodendrocyte glycoprotein (MOG) plays a crucial role in the nervous system as a minor component of the myelin sheath. It is pivotal in mediating homophilic cell-cell adhesion, potentially influencing the completion and maintenance of the myelin sheath, alongside facilitating cell-cell communication. Additionally, MOG acts as a receptor for rubella virus, indicating its significance in microbial infection.
Therapeutic significance:
MOG's involvement in Narcolepsy 7, a neurological disorder characterized by excessive daytime sleepiness and cataplexy, underscores its therapeutic significance. The disorder's link to variants affecting the MOG gene highlights the potential for targeted therapeutic strategies aimed at mitigating or managing symptoms of narcolepsy and improving patient quality of life.